Table 3 Stepwise multivariate models to examine the independent predictors of 90-day mortality, early antibody response* and viral clearance among critically ill patients with Middle East Respiratory Syndrome (MERS).

From: Kinetics of antibody response in critically ill patients with Middle East respiratory syndrome and association with mortality and viral clearance

Variables

Odds ratio (CI)

P-value

Early antibody response

Any comorbidity

4.19 (0.85, 20.71)

0.08

Days from onset of symptoms to ICU admission (for each day increase)

0.91 (0.83, 1.00)

0.06

 

Hazard ratio (CI)

 

90-day mortality

Early antibody response

0.31 (0.10, 0.96)

0.04

Any comorbidity

5.00 (1.42, 17.62)

0.01

MERS-CoV RNA clearance

Any comorbidity

0.12 (0.04, 0.39)

0.0004

  1. *Early antibody response = positive on day 1 or day 3; CI: Confidence Interval; ICU: Intensive care unit.
  2. All analyses were adjusted for age, any comorbidity, Sequential Organ Failure Assessment (SOFA) and days from onset of symptoms to ICU admission.
  3. For MERS-CoV RNA, hazard ratio < 1 signifies delay in clearance.
Back to article page